Bristol-Myers Squibb Company (BMY) 59.15 $BMY
Final Glance: Pharmaceuticals companies
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
This Cancer Drug War Is Just Getting Started
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 24, 11:41AM CST
The Food and Drug Administration approved Bristol-Myers Squibb 's Opdivo to treat melanoma on Monday. That's not very surprising given the strong clinical trial data the cancer drug has posted so far. In a trial of 120 patients without any other...
MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Early Glance: Pharmaceuticals companies
AP - Wed Dec 24, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
'Mad Money' Lightning Round: SunTrust Banks Is Terrific
at The Street - Wed Dec 24, 5:00AM CST
Cramer says by GW Pharmaceuticals for the long term but avoid Arlington Asset Management and Prospect Capital.
EYES: 11.01 (+0.86), GWPH: 68.08 (+1.82), COG: 30.21 (-0.39), STI: 42.43 (-0.18), AI: 27.70 (-0.12), BMY: 59.15 (-0.01), RRC: 55.73 (-1.27), PSEC: 8.59 (-0.02)
Jim Cramer's 'Mad Money' Recap: Here Are 10 Stocks to Buy on Strong GDP Data
at The Street - Tue Dec 23, 7:26PM CST
Kimberly-Clark, Walgreen and Starbucks are among Cramer's winners on today's GDP number.
RH: 96.97 (-0.16), EYES: 11.01 (+0.86), ETN: 69.30 (-0.09), HON: 101.96 (-0.02), KMB: 117.77 (-0.21), IBB: 299.80 (+5.12), BMY: 59.15 (-0.01), PLKI: 55.50 (+0.01), MAR: 78.35 (-0.19), BA: 131.24 (+1.21), RRC: 55.73 (-1.27), VSAT: 63.75 (-0.20), SBUX: 81.27 (-0.16), NVGS: 20.00 (+2.10), COG: 30.21 (-0.39), GILD: 91.29 (+1.84), GWPH: 68.08 (+1.82), STI: 42.43 (-0.18), COST: 143.65 (-0.50), AI: 27.70 (-0.12), WAG: 76.67 (+0.16), PSEC: 8.59 (-0.02), EPD: 35.45 (+0.25)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 3.11% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:54PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.70 to a high of $61.77. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $59.57 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 59.15 (-0.01)
Watch for Bristol-Myers Squibb to Potentially Rebound After Falling 3.11% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 3:53PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.70 to a high of $61.77. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $59.57 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 59.15 (-0.01)
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)
Midday Glance: Pharmaceuticals companies
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
Stocks Cheering This Festive Season: Featured Research on Bristol-Myers, Rite Aid, Boeing, TASER and BioCryst
PR Newswire - Tue Dec 23, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Bristol-Myers (NYSE: BMY), Rite Aid (NYSE: RAD), Boeing (NYSE: BA), TASER (NASDAQ: TASR), and BioCryst (NASDAQ: BCRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
BCRX: 11.83 (+0.76), BMY: 59.15 (-0.01), TASR: 26.86 (+0.84), BA: 131.24 (+1.21), RAD: 7.26 (-0.09)
Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Bristol-Myers Squibb wins US FDA approval for Opdivo (nivolumab) for treating metastatic melanoma
M2 - Tue Dec 23, 5:33AM CST
Pharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) reported on Monday the receipt of the US Food and Drug Administration (FDA) approval for Opdivo (nivolumab).
BMY: 59.15 (-0.01)
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration
Business Wire - Mon Dec 22, 4:21PM CST
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Metastatic melanoma is the deadliest form of skin cancer, and despite recent advances, there are limited treatment options available for patients who have been previously treated with approved agents.
BMY: 59.15 (-0.01)
FDA clears Bristol-Myers cancer drug
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 2:12PM CST
BMY: 59.15 (-0.01)
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)
Business Wire - Mon Dec 22, 2:11PM CST
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab).
BMY: 59.15 (-0.01)
Final Glance: Pharmaceuticals companies
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
This Cancer Drug War Is Just Getting Started
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 24, 11:41AM CST
The Food and Drug Administration approved Bristol-Myers Squibb 's Opdivo to treat melanoma on Monday. That's not very surprising given the strong clinical trial data the cancer drug has posted so far. In a trial of 120 patients without any other...
MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Early Glance: Pharmaceuticals companies
AP - Wed Dec 24, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
'Mad Money' Lightning Round: SunTrust Banks Is Terrific
at The Street - Wed Dec 24, 5:00AM CST
Cramer says by GW Pharmaceuticals for the long term but avoid Arlington Asset Management and Prospect Capital.
EYES: 11.01 (+0.86), GWPH: 68.08 (+1.82), COG: 30.21 (-0.39), STI: 42.43 (-0.18), AI: 27.70 (-0.12), BMY: 59.15 (-0.01), RRC: 55.73 (-1.27), PSEC: 8.59 (-0.02)
Jim Cramer's 'Mad Money' Recap: Here Are 10 Stocks to Buy on Strong GDP Data
at The Street - Tue Dec 23, 7:26PM CST
Kimberly-Clark, Walgreen and Starbucks are among Cramer's winners on today's GDP number.
RH: 96.97 (-0.16), EYES: 11.01 (+0.86), ETN: 69.30 (-0.09), HON: 101.96 (-0.02), KMB: 117.77 (-0.21), IBB: 299.80 (+5.12), BMY: 59.15 (-0.01), PLKI: 55.50 (+0.01), MAR: 78.35 (-0.19), BA: 131.24 (+1.21), RRC: 55.73 (-1.27), VSAT: 63.75 (-0.20), SBUX: 81.27 (-0.16), NVGS: 20.00 (+2.10), COG: 30.21 (-0.39), GILD: 91.29 (+1.84), GWPH: 68.08 (+1.82), STI: 42.43 (-0.18), COST: 143.65 (-0.50), AI: 27.70 (-0.12), WAG: 76.67 (+0.16), PSEC: 8.59 (-0.02), EPD: 35.45 (+0.25)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 3.11% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:54PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.70 to a high of $61.77. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $59.57 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 59.15 (-0.01)
Watch for Bristol-Myers Squibb to Potentially Rebound After Falling 3.11% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 3:53PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.70 to a high of $61.77. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $59.57 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 59.15 (-0.01)
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)
Midday Glance: Pharmaceuticals companies
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
Stocks Cheering This Festive Season: Featured Research on Bristol-Myers, Rite Aid, Boeing, TASER and BioCryst
PR Newswire - Tue Dec 23, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Bristol-Myers (NYSE: BMY), Rite Aid (NYSE: RAD), Boeing (NYSE: BA), TASER (NASDAQ: TASR), and BioCryst (NASDAQ: BCRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
BCRX: 11.83 (+0.76), BMY: 59.15 (-0.01), TASR: 26.86 (+0.84), BA: 131.24 (+1.21), RAD: 7.26 (-0.09)
Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Bristol-Myers Squibb wins US FDA approval for Opdivo (nivolumab) for treating metastatic melanoma
M2 - Tue Dec 23, 5:33AM CST
Pharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) reported on Monday the receipt of the US Food and Drug Administration (FDA) approval for Opdivo (nivolumab).
BMY: 59.15 (-0.01)
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration
Business Wire - Mon Dec 22, 4:21PM CST
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Metastatic melanoma is the deadliest form of skin cancer, and despite recent advances, there are limited treatment options available for patients who have been previously treated with approved agents.
BMY: 59.15 (-0.01)
FDA clears Bristol-Myers cancer drug
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 2:12PM CST
BMY: 59.15 (-0.01)
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)
Business Wire - Mon Dec 22, 2:11PM CST
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab).
BMY: 59.15 (-0.01)
